Zobrazeno 1 - 5
of 5
pro vyhledávání: '"S I, Khemchandani"'
Autor:
H L, Trivedi, H, Kaneku, P I, Terasaki, A, Feroz, A V, Vanikar, V B, Trivedi, S I, Khemchandani, S D, Dave, P R, Modi, F, Jahr, A, Idica, M J, Everly
Publikováno v:
Clinical transplants.
A total of 69 individuals received a kidney from a living donor after a TLI-based clonal deletion protocol with no post-transplant maintenance immunosuppression planned. If needed, immunosuppression was started on a patient-specific basis, adding one
Autor:
H, Kaneku, A, Idica, M J, Everly, P I, Terasaki, A, Feroz, A V, Vanikar, V, Shankar, V B, Trivedi, P R, Modi, S I, Khemchandani, S D, Dave, H L, Trivedi
Publikováno v:
Clinical transplants.
1. A total of 61 patients were treated with a clonal deletion protocol and transplanted without planned post-transplant immunosuppression. 2. Twenty-nine (48%) patients did not develop any donor-specific anti-HLA antibodies after the transplant, with
Autor:
A, Idica, H, Kaneku, M J, Everly, H L, Trivedi, A, Feroz, A V, Vanikar, V, Shankar, V B, Trivedi, P R, Modi, S I, Khemchandani, S D, Dave, P I, Terasaki
Publikováno v:
Clinical transplants.
We show the ability of bortezomib to remove donor-specific HLA antibody from kidney allograft patients, the drug acting as a proteasome inhibitor, providing targeted therapy against antibody-producing plasma cells. Ten out of thirteen patients (77%)
Autor:
Oura, T, Yamashita, K, Suzuki, T, Fukumori, D, Miura, T, Kubota, K, Taniguchi, M, Shimamura, T, Furukawa, H, Todo, S
Publikováno v:
Transplantation; 2008 Supplement 2, Vol. 86, p67-67, 1p
Autor:
Trivedi, H L., Terasaki, P I., Firoz, A, Vanikar, A V., Shankar, V, Trivedi, V B., Kaneku, H, Idica, A, Modi, P R., Khemchandani, S I.
Publikováno v:
Transplantation; 2008 Supplement 2, Vol. 86, p67-67, 1p